US2004247700A1PendingUtilityA1

Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

48
Priority: Jul 17, 2001Filed: Jul 17, 2002Published: Dec 9, 2004
Est. expiryJul 17, 2021(expired)· nominal 20-yr term from priority
A61P 29/00A61K 36/00A61K 31/56A61K 31/19A61K 45/06A61P 17/06A61K 31/366A61K 36/9066A61K 31/075A61P 19/02A61K 31/365A61K 31/704A61K 31/047A61P 17/10A61K 31/12
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions comprising an effective amount of a curcuminoid species and an effective amount of a diterpene lactone species, a triterpene species or derivatives thereof that have a synergistic effect on specific inhibition of inducible COX-2 activity and have minimal effect on COX-1 activity are disclosed. Methods of using the compositions for providing synergistic anti-inflammatory effects are also disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A composition comprising an effective amount of a curcuminoid species and an effective amount of a diterpene lactone species, a triterpene species or derivatives thereof, wherein the ratio of the curcuminoid species and the diterpene lactone species, the triterpene species or derivatives thereof is from 1:10 to 10:1, said composition when administered to an animal, has a synergistic effect on specific inhibition of inducible COX-2 activity and has minimal effect on COX-1 activity.  
     
     
         2 . The composition of  claim 1  wherein the curcuminoid species is pharmaceutical grade curcumin, demethoxycurcurmin or bisdemethoxycurcumin.  
     
     
         3 . The composition of  claim 1  wherein the diterpene lactone species is a member selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, selenoandrographolide, homoandrographolide, andrographan, amdrographon, andrographosterin, 14-deoxy-11-oxoandrographolide, 14-deoxy-11, 12-didehydroandrographolide, andrographiside and edelin lactone.  
     
     
         4 . The composition of  claim 1  wherein the triterpene species is a member selected from the group consisting of ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, 2-a-3-a-dihydroxyurs-12-3n-28-oic acid, 2-a-hydroxyursolic acid, 3-oxo-ursolic acid, celastrol, friedelin, tritophenolide, uvaol, eburicoic acid, glycyrrhizin, gypsogenin, oleanolic acid-3-acetate, pachymic acid, pinicolic acid, sophoradiol, soyasapogenol A, soyasapogenol B, tumulosic acid, ursolic acid-3-acetate and sitosterol.  
     
     
         5 . The composition of  claim 1 , wherein at least one member of the curcuminoid species, the diterpene lactone species and the triterpene species is derived from plants) or plant extract(s).  
     
     
         6 . The composition of  claim 1  wherein at one member of the curcuminoid species, the diterpene lactone species and the triterpene species is conjugated with a compound selected from the group consisting of mono- or di-saccharides, amino acids, sulfates, succinate, acetate and glutathione.  
     
     
         7 . The composition of  claim 1 , further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, carbohydrates, glucosamine, chondrotin sulfate and aminosugars.  
     
     
         8 . A method of supplementing the dietary needs of animals suffering symptoms of inflammation, arthritis, acne rosacea or psoriasis comprising administering to said animals a composition comprising an effective amount of a curcuminoid species and an effective amount of a diterpene lactone species or a triterpene species or derivatives thereof such that said composition has a synergistic effect on specific inhibition of Inducible COX-2 activity and having minimal effect on COX-1 activity.  
     
     
         9 . The method of  claim 8  wherein the composition is formulated in a dosage form such that said administration provides from 0.001 to 30.0 mg body weight per day of each curcuminoid species, and from 0.5 to 20.0 mg/kg body weight per day of each diterpene lactones species or triterpenes species.  
     
     
         10 . The method of  claim 8 , wherein the composition is administered in an amount sufficient to maintain a serum concentration of 0.1 to 50 μM of each curcuminoid species, and from 0.001 to 50 μM of each diterpene lactone species or triterpene species.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.